Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
|Articles|October 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 10
- Volume 16
- Issue 10
Merck to donate 3 million doses of Gardasil to poor countries
Merck to donate 3 million doses of Gardasil to poor countries
Advertisement
NEW YORKMerck & Co. has committed to donate at least 3 million doses of it human papillomavirus vaccine Gardasil over the next 5 years for use in demonstration projects in lowest income nations throughout the world. The company made the announcement at the Clinton Global Initiative 2007 meeting. "We are committing to the vaccination of 1 million females against cervical cancer," said Merck's Margaret McGlynn.
Articles in this issue
about 19 years ago
Bill aims to 'revitalize' FDA by adding powers and databasesabout 19 years ago
New myeloma trial results; two new studies initiatedabout 19 years ago
Neoadjuvant trastuzumab increases pCR ratesabout 19 years ago
Court rejects right of terminally ill to unproven drugsabout 19 years ago
Sorafenib improves overall survival in Asian HCC ptsabout 19 years ago
Skipping tam doses increases risk of deathabout 19 years ago
The SGR: The madness behind physician payment fee cutsabout 19 years ago
Dr. Pegram seeks new breast cancer challenges at Miamiabout 19 years ago
SearchMedica.com receives awardAdvertisement
Related to this article
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pirtobrutinib in Frontline CLL/SLL
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5